Clinical Trial Update: Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females [Phase 1]

View source ↗

Summary

Phase 1 study evaluating drug interaction between erenumab (AMG 334) and combined oral contraceptive in healthy females; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Headache
• Migraine

Drugs mentioned

• Combined oral contraceptive
• erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Headache, Migraine | Phase 1 | Status: COMPLETED | Results posted: 2018-12-20